| |
 |
|
|
|
|
| |
|
| Latest News |
|
| February 4th, 2010 |  | | Micromet to Host Annual Research & Development Day on February 10, 2010 | | | | Bethesda, MD, February 4, 2010 -- Micromet, Inc. (Nasdaq: MITI) today announced that it will host a Research & Development Day for the investment community on Wednesday, February 10, 2010 from 8:00 AM – 11:00 AM ET at the Yale Club in New York City. Members of the Company's leadership team will outline near-term development plans for the Company's lead product candidate blinatumomab (MT103) and will provide an update on the Company's earlier stage BiTE® antibodies.
Interested parties may access a live audio webcast of the presentation via the homepage of the Micromet website, www.micromet-inc.com or by dialing 866-700-7477 (U.S) or 617-213-8840 (International), passcode: 23649136.
About Micromet, Inc.
Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including sanofi-aventis, Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed. Additional information can be found at www.micromet-inc.com
Contact:
Jennifer Neiman
Director, Corporate Communications
Micromet, Inc.
240-235-0246
jennifer.neiman@micromet-inc.com | |
|
|
|
|
| |
|
|
|
|
|
|
|
